Palisade Bio Inc (PALI) Stock Forecast & Price Target
Palisade Bio Inc · NASDAQ
$2.01-0.03 (-1.23%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 7 firms covering Palisade Bio Inc, 7 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $5.00 to $25.00 (about 5.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $10.14 sits 406% above the current $2.01. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.06 next quarter toward $-0.29 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 ratings
Moderate Buy
Strong Buy00%
Buy7100%
Hold00%
Sell00%
Strong Sell00%
Based on 7 analysts giving stock ratings to Palisade Bio Inc.
As of Jul, 7 of 7 firms rate PALI a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
PALI EPS & revenue forecast
EPS · NEXT QUARTER
$-0.06
Range $-0.12 – $-0.04 · 7 analysts · -84% YoY
Next period, 7 analysts expect Palisade Bio Inc to earn $-0.06 a share (range $-0.12 – $-0.04), versus $-0.38 a year earlier. Full-year consensus is $-0.24, growing to $-0.29 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 7 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Palisade Bio Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PALI.
#1
Yasmeen Rahimi
Piper Sandler · Rank #152
Buy
$25.00+1146.9% to target
Overall win rate
34%
+ Follow
#2
Mitchell Kapoor
HC Wainwright & Co. · Rank #165
Buy
$7.00+249.1% to target
Overall win rate
34%
+ Follow
#3
Leland Gershell
Oppenheimer · Rank #254
Buy
$8.00+299.0% to target
Overall win rate
37%
+ Follow
#4
WW
William Wood
B. Riley Securities
Buy
$7.00+249.1% to target
Coverage
—
+ Follow
#5
Andy Chen
Wolfe Research
Buy
$7.00+249.1% to target
Coverage
—
+ Follow
PALI stock forecast FAQ
What is PALI's average 12-month price target?+
The 7 analysts with a live target average $10.14 for Palisade Bio Inc over the next 12 months, ranging from a $25.00 high to a $5.00 low.
Is PALI stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 7 analyst ratings, 7 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for PALI?+
The Street-high target is $25.00 (Piper Sandler), and the Street-low is $5.00 (Stifel). The average of all 7 active targets is $10.14.
How many Wall Street analysts cover PALI?+
7 analysts have an active rating on Palisade Bio Inc, and 7 firms carry a live 12-month price target.
Who is the most accurate analyst covering PALI?+
Among analysts who currently cover PALI, Yasmeen Rahimi of Piper Sandler has the strongest overall Quantellect track record (Rank #152). Their current call is Buy with a $25.00 target.
What is Palisade Bio Inc's projected EPS for next quarter?+
The consensus estimate is $-0.06 per share (range $-0.12 – $-0.04) across 7 analysts. Full-year EPS is projected at $-0.24, rising to $-0.29 the following year.
How much revenue is Palisade Bio Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading PALI lately?+
As of Jul, 7 of 7 firms rate PALI a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PALI calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
